Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Peroxicretion: a novel secretion pathway in the eukaryotic cell.

Sagt CM, ten Haaft PJ, Minneboo IM, Hartog MP, Damveld RA, van der Laan JM, Akeroyd M, Wenzel TJ, Luesken FA, Veenhuis M, van der Klei I, de Winde JH.

BMC Biotechnol. 2009 May 20;9:48. doi: 10.1186/1472-6750-9-48.

2.

Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.

Uberla K, Rosenwirth B, Ten Haaft P, Heeney J, Sutter G, Erfle V.

J Med Primatol. 2007 Feb;36(1):2-9.

PMID:
17359459
3.

Transmission of simian immunodeficiency virus SIVcpz and the evolution of infection in the presence and absence of concurrent human immunodeficiency virus type 1 infection in chimpanzees.

Heeney JL, Rutjens E, Verschoor EJ, Niphuis H, ten Haaft P, Rouse S, McClure H, Balla-Jhagjhoorsingh S, Bogers W, Salas M, Cobb K, Kestens L, Davis D, van der Groen G, Courgnaud V, Peeters M, Murthy KK.

J Virol. 2006 Jul;80(14):7208-18.

4.

Importance of the N-distal AP-2 binding element in Nef for simian immunodeficiency virus replication and pathogenicity in rhesus macaques.

Brenner M, Münch J, Schindler M, Wildum S, Stolte N, Stahl-Hennig C, Fuchs D, Mätz-Rensing K, Franz M, Heeney J, Ten Haaft P, Swigut T, Hrecka K, Skowronski J, Kirchhoff F.

J Virol. 2006 May;80(9):4469-81.

5.

Readily acquired secondary infections of human and simian immunodeficiency viruses following single intravenous exposure in non-human primates.

ten Haaft P, Verschoor EJ, Verstrepen B, Niphuis H, Dubbes R, Koornstra W, Bogers W, Rosenwirth B, Heeney JL.

J Gen Virol. 2004 Dec;85(Pt 12):3735-45.

PMID:
15557247
6.

Direct inoculation of simian immunodeficiency virus from sooty mangabeys in black mangabeys (Lophocebus aterrimus): first evidence of AIDS in a heterologous African species and different pathologic outcomes of experimental infection.

Apetrei C, Gormus B, Pandrea I, Metzger M, ten Haaft P, Martin LN, Bohm R, Alvarez X, Koopman G, Murphey-Corb M, Veazey RS, Lackner AA, Baskin G, Heeney J, Marx PA.

J Virol. 2004 Nov;78(21):11506-18.

7.

CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection.

Bogers WM, Bergmeier LA, Oostermeijer H, ten Haaft P, Wang Y, Kelly CG, Singh M, Heeney JL, Lehner T.

Vaccine. 2004 Aug 13;22(23-24):2974-84.

PMID:
15356916
8.

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, Cara A, Negri DR, Buttò S, Fiorelli V, Tripiciano A, Scoglio A, Caputo A, Borsetti A, Ridolfi B, Bona R, ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Ciccozzi M, Heeney J, Titti F, Cafaro A, Ensoli B.

Vaccine. 2004 Sep 3;22(25-26):3258-69.

PMID:
15308348
9.

A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection.

Bogers WM, Bergmeier LA, Ma J, Oostermeijer H, Wang Y, Kelly CG, Ten Haaft P, Singh M, Heeney JL, Lehner T.

AIDS. 2004 Jan 2;18(1):25-36.

PMID:
15090826
10.

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.

Mooij P, Nieuwenhuis IG, Knoop CJ, Doms RW, Bogers WM, Ten Haaft PJ, Niphuis H, Koornstra W, Bieler K, Köstler J, Morein B, Cafaro A, Ensoli B, Wagner R, Heeney JL.

J Virol. 2004 Apr;78(7):3333-42.

12.

Replication, immunogenicity, and protective properties of live-attenuated simian immunodeficiency viruses expressing interleukin-4 or interferon-gamma.

Stahl-Hennig C, Gundlach BR, Dittmer U, ten Haaft P, Heeney J, Zou W, Emilie D, Sopper S, Uberla K.

Virology. 2003 Jan 20;305(2):473-85.

13.

T-cell receptor:CD3 down-regulation is a selected in vivo function of simian immunodeficiency virus Nef but is not sufficient for effective viral replication in rhesus macaques.

Münch J, Janardhan A, Stolte N, Stahl-Hennig C, Ten Haaft P, Heeney JL, Swigut T, Kirchhoff F, Skowronski J.

J Virol. 2002 Dec;76(23):12360-4.

14.

HIV-1 Tat-based vaccines: from basic science to clinical trials.

Fanales-Belasio E, Cafaro A, Cara A, Negri DR, Fiorelli V, Butto S, Moretti S, Maggiorella MT, Baroncelli S, Michelini Z, Tripiciano A, Sernicola L, Scoglio A, Borsetti A, Ridolfi B, Bona R, Ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Vardas E, Magnani M, Laguardia E, Caputo A, Titti F, Ensoli B.

DNA Cell Biol. 2002 Sep;21(9):599-610. Review.

PMID:
12396602
15.

MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys.

Mühl T, Krawczak M, Ten Haaft P, Hunsmann G, Sauermann U.

J Immunol. 2002 Sep 15;169(6):3438-46.

16.

Longitudinal comparison of virus load parameters and CD8 T-cell suppressive capacity in two SIVcpz-infected chimpanzees.

Ondoa P, Kestens L, Davis D, Vereecken C, Willems B, Fransen K, Vingerhoets J, Zissis G, ten Haaft P, Heeney J, van der Groen G.

J Med Primatol. 2001 Oct;30(5):243-53.

PMID:
11990239
17.

Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques.

Nilsson C, Sutter G, Walther-Jallow L, ten Haaft P, Akerblom L, Heeney J, Erfle V, Böttiger P, Biberfeld G, Thorstensson R.

J Gen Virol. 2002 Apr;83(Pt 4):807-18.

PMID:
11907330
18.
19.

Differences in early virus loads with different phenotypic variants of HIV-1 and SIV(cpz) in chimpanzees.

ten Haaft P, Murthy K, Salas M, McClure H, Dubbes R, Koornstra W, Niphuis H, Davis D, van der Groen G, Heeney J.

AIDS. 2001 Nov 9;15(16):2085-92.

PMID:
11684927
20.

Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection.

ten Haaft P, Almond N, Biberfeld G, Cafaro A, Cranage M, Ensoli B, Hunsmann G, Polyanskaya N, Stahl-Hennig C, Thortensson R, Titti F, Heeney J.

J Med Primatol. 2001 Aug;30(4):207-14.

PMID:
11555139
21.

Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIV(macJ5) on the kinetics of SIV replication in cynomolgus monkeys.

Negri DR, Baroncelli S, Michelini Z, Macchia I, Belli R, Catone S, Incitti F, ten Haaft P, Corrias F, Cranage MP, Polyanskaya N, Norley S, Heeney J, Verani P, Titti F.

J Med Primatol. 2001 Aug;30(4):197-206.

PMID:
11555138
22.

Simian immunodeficiency virus in which nef and U3 sequences do not overlap replicates efficiently in vitro and in vivo in rhesus macaques.

Münch J, Adam N, Finze N, Stolte N, Stahl-Hennig C, Fuchs D, Ten Haaft P, Heeney JL, Kirchhoff F.

J Virol. 2001 Sep;75(17):8137-46.

23.

Protection from secondary human immunodeficiency virus type 1 infection in chimpanzees suggests the importance of antigenic boosting and a possible role for cytotoxic T cells.

Balla-Jhagjhoorsingh SS, Mooij P, ten Haaft PJ, Bogers WM, Teeuwsen VJ, Koopman G, Heeney JL.

J Infect Dis. 2001 Jul 15;184(2):136-43. Epub 2001 Jun 8.

PMID:
11424009
24.

Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys.

Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R.

J Gen Virol. 2001 Jul;82(Pt 7):1601-12.

PMID:
11413371
25.

An in vivo model for HIV resistance development.

Zuber B, Böttiger D, Benthin R, ten Haaft P, Heeney J, Wahren B, Oberg B.

AIDS Res Hum Retroviruses. 2001 May 1;17(7):631-5.

PMID:
11375059
26.

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.

Nilsson C, Mäkitalo B, Berglund P, Bex F, Liljeström P, Sutter G, Erfle V, ten Haaft P, Heeney J, Biberfeld G, Thorstensson R.

Vaccine. 2001 May 14;19(25-26):3526-36.

PMID:
11348720
27.

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, Goletti D, Borsetti A, Pace M, Fanales-Belasio E, Ridolfi B, Negri DR, Sernicola L, Belli R, Corrias F, Macchia I, Leone P, Michelini Z, ten Haaft P, Buttò S, Verani P, Ensoli B.

Vaccine. 2001 Apr 6;19(20-22):2862-77.

PMID:
11282197
28.

Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: lack of enhancement by nonneutralizing antibody.

Polyanskaya N, Bergmeier LA, Sharpe SA, Cook N, Leech S, Hall G, Dennis M, ten Haaft P, Heeney J, Manca F, Lehner T, Cranage MP.

Virology. 2001 Jan 20;279(2):527-38.

29.

Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

Mooij P, Bogers WM, Oostermeijer H, Koornstra W, Ten Haaft PJ, Verstrepen BE, Van Der Auwera G, Heeney JL.

J Virol. 2000 May;74(9):4017-27.

30.

Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.

Spring M, Stahl-Hennig C, Stolte N, Bischofberger N, Heeney J, ten Haaft P, Tenner-Ràcz K, Ràcz P, Lorenzen D, Hunsmann G, Dittmer U.

Virology. 2001 Jan 5;279(1):221-32.

31.

A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens.

Heeney JL, Koopman G, Rosenwirth B, Bogers W, van Dijk J, Nieuwenhuis I, Niphuis H, ten Haaft P, Hanke T, Rhodes G, Berglund P, Burny A, Bex F, Sutter G, Liljeström P.

J Med Primatol. 2000 Aug;29(3-4):268-73.

PMID:
11085589
32.

SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.

Cafaro A, Caputo A, Maggiorella MT, Baroncelli S, Fracasso C, Pace M, Borsetti A, Sernicola L, Negri DR, Ten Haaft P, Betti M, Michelini Z, Macchia I, Fanales-Belasio E, Belli R, Corrias F, Buttò S, Verani P, Titti F, Ensoli B.

J Med Primatol. 2000 Aug;29(3-4):193-208.

PMID:
11085582
33.

The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques.

Holterman L, Niphuis H, Koornstra W, Dubbes R, ten Haaft P, Heeney JL.

J Gen Virol. 2000 Jul;81(Pt 7):1719-26.

PMID:
10859377
34.

Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.

Rosenwirth B, ten Haaft P, Bogers WM, Nieuwenhuis IG, Niphuis H, Kuhn EM, Bischofberger N, Heeney JL, Uberla K.

J Virol. 2000 Feb;74(4):1704-11.

35.

Specific passage of simian immunodeficiency virus from end-stage disease results in accelerated progression to AIDS in rhesus macaques.

Holterman L, Niphuis H, ten Haaft PJ, Goudsmit J, Baskin G, Heeney JL.

J Gen Virol. 1999 Dec;80 ( Pt 12):3089-97.

PMID:
10567639
36.

Co-receptor usage of BOB/GPR15 in addition to CCR5 has no significant effect on replication of simian immunodeficiency virus in vivo.

Pöhlmann S, Stolte N, Münch J, Ten Haaft P, Heeney JL, Stahl-Hennig C, Kirchhoff F.

J Infect Dis. 1999 Nov;180(5):1494-502.

PMID:
10515808
37.

The acidic region and conserved putative protein kinase C phosphorylation site in Nef are important for SIV replication in rhesus macaques.

Carl S, Iafrate AJ, Lang SM, Stahl-Hennig C, Kuhn EM, Fuchs D, Mätz-Rensing K, ten Haaft P, Heeney JL, Skowronski J, Kirchhoff F.

Virology. 1999 Apr 25;257(1):138-55.

38.

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

Verschoor EJ, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B, Sun Y, Morein B, Akerblom L, Fuller DH, Barnett SW, Heeney JL.

J Virol. 1999 Apr;73(4):3292-300.

39.

Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees.

Bogers WM, Koornstra WH, Dubbes RH, ten Haaft PJ, Verstrepen BE, Jhagjhoorsingh SS, Haaksma AG, Niphuis H, Laman JD, Norley S, Schuitemaker H, Goudsmit J, Hunsmann G, Heeney JL, Wigzell H.

J Gen Virol. 1998 Dec;79 ( Pt 12):2895-903.

PMID:
9880002
40.
41.

A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.

Mooij P, van der Kolk M, Bogers WM, ten Haaft PJ, Van Der Meide P, Almond N, Stott J, Deschamps M, Labbe D, Momin P, Voss G, Von Hoegen P, Bruck C, Heeney JL.

AIDS. 1998 Mar 26;12(5):F15-22.

PMID:
9543435
42.

Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta.

Bogers WM, Dubbes R, ten Haaft P, Niphuis H, Cheng-Mayer C, Stahl-Hennig C, Hunsmann G, Kuwata T, Hayami M, Jones S, Ranjbar S, Almond N, Stott J, Rosenwirth B, Heeney JL.

Virology. 1997 Sep 15;236(1):110-7.

43.

Intact CCR-5 coreceptors in HIV-1-infected chimpanzees.

ten Haaft PJ, Murthy KK, Verstrepen BE, Eichberg JW, Heeney JL.

AIDS. 1997 Aug;11(10):1291-3. No abstract available.

PMID:
9256948
44.

Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS.

Heeney J, Bogers W, Buijs L, Dubbes R, ten Haaft P, Koornstra W, Niphuis H, Nara P, Teeuwsen V.

Immunol Lett. 1996 Jun;51(1-2):45-52.

PMID:
8811344
45.
46.

Virus load in chimpanzees infected with human immunodeficiency virus type 1: effect of pre-exposure vaccination.

ten Haaft P, Cornelissen M, Goudsmit J, Koornstra W, Dubbes R, Niphuis H, Peeters M, Thiriart C, Bruck C, Heeney JL.

J Gen Virol. 1995 Apr;76 ( Pt 4):1015-20.

PMID:
9049351
47.

Infectivity and virulence of cell-associated SIVmac after single passage in vivo.

Niphuis H, Dubbes RH, ten Haaft PJ, Koornstra WH, Bontrop RE, Cranage MP, Heeney JL.

AIDS. 1994 Dec;8(12):1730-1. No abstract available.

PMID:
7888125
48.

Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.

de Vries P, Heeney JL, Boes J, Dings ME, Hulskotte EG, Dubbes R, Koornstra W, ten Haaft P, Akerblom L, Eriksson S, et al.

Vaccine. 1994 Nov;12(15):1443-52.

PMID:
7887023
49.

Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells.

Heeney JL, van Els C, de Vries P, ten Haaft P, Otting N, Koornstra W, Boes J, Dubbes R, Niphuis H, Dings M, Cranage M, Norley S, Jonker M, Bontrop RE, Osterhaus A.

J Exp Med. 1994 Aug 1;180(2):769-74.

50.

Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge.

Heeney JL, Holterman L, ten Haaft P, Dubbes R, Koornstra W, Teeuwsen V, Bourquin P, Norley S, Niphuis H.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S117-21.

PMID:
7865285

Supplemental Content

Loading ...
Support Center